R&D

News

Vertex licenses back CRISPR compounds from German Merck

US pharma Vertex has licensed back two gene editing compounds that can be used with CRISPR/Cas9 technology, from Germany’s Merck KGaA.

News

NICE assessments could reform in new superbug plan

The UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a new NHS reimbursement scheme backed by NICE to encourage pharma to develop

News

CRISPR gene editing stocks fall after Editas CEO resigns

Shares in firms developing therapies based on CRISPR gene editing technology have fallen after the resignation of the CEO of one of the leading biotechs in the field, Editas.

News

Lilly stops promoting cancer drug after shock trial failure

Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop p

News

Novartis and Oxford University begin R&D tie-up

Novartis and Oxford University have begun a partnership that will attempt to use artificial intelligence to predict how patients will respond to new and existing treatments for inflammatory

News